Search research articles
Contact Us
Filters
Showing results (61-70 of 87) with videos related to
Page
of 9
Sort By:
Gynecologic Oncology
|
February 23, 2019
Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients
V Rodriguez-Freixinos, S Lheureux, V Mandilaras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer
A Patnaik, E K Rowinsky, B K Tammara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 16, 2017
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
L R Yates, J Seoane, C Le Tourneau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2003
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group
C A Townsley, K Chi, D S Ernst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, L L Siu, J Nemunaitis, et al.
Oral Oncology
|
May 29, 2020
Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck
D Day, A Prawira, A Spreafico, et al.
ESMO Open
|
June 5, 2025
Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer
M J Elliott, J Kim, A Dou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 24, 2014
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx
H H Loong, E Winquist, J Waldron, et al.
Gynecologic Oncology
|
January 8, 2017
Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)
A Spreafico, A M Oza, B A Clarke, et al.
British Journal of Cancer
|
October 13, 2006
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
I Duran, J Kortmansky, D Singh, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 87) with videos related to
Sort By:
Page
of 9
Gynecologic Oncology
|
February 23, 2019
Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients
V Rodriguez-Freixinos, S Lheureux, V Mandilaras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2000
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer
A Patnaik, E K Rowinsky, B K Tammara, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 16, 2017
The European Society for Medical Oncology (ESMO) Precision Medicine Glossary
L R Yates, J Seoane, C Le Tourneau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2003
Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group
C A Townsley, K Chi, D S Ernst, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies
M Hidalgo, L L Siu, J Nemunaitis, et al.
Oral Oncology
|
May 29, 2020
Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck
D Day, A Prawira, A Spreafico, et al.
ESMO Open
|
June 5, 2025
Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer
M J Elliott, J Kim, A Dou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 24, 2014
Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx
H H Loong, E Winquist, J Waldron, et al.
Gynecologic Oncology
|
January 8, 2017
Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC)
A Spreafico, A M Oza, B A Clarke, et al.
British Journal of Cancer
|
October 13, 2006
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
I Duran, J Kortmansky, D Singh, et al.
Page
of 9